Other formats:
BibTeX
LaTeX
RIS
@article{2254099,
author = {Eyer, Luděk and SeleyandRadtke, Katherine and Růžek, Daniel},
article_number = {February},
doi = {http://dx.doi.org/10.1016/j.antiviral.2022.105504},
keywords = {Tick-borne encephalitis; Tick-borne encephalitis virus; Antivirals; Monoclonal antibodies; Immunotherapy},
language = {eng},
issn = {0166-3542},
journal = {Antiviral Research},
title = {New directions in the experimental therapy of tick-borne encephalitis.},
url = {https://doi.org/10.1016/j.antiviral.2022.105504},
volume = {210},
year = {2023}
}
TY - JOUR
ID - 2254099
AU - Eyer, Luděk - Seley-Radtke, Katherine - Růžek, Daniel
PY - 2023
TI - New directions in the experimental therapy of tick-borne encephalitis.
JF - Antiviral Research
VL - 210
IS - February
SP - 1-6
EP - 1-6
PB - Elsevier B.V.
SN - 01663542
KW - Tick-borne encephalitis
KW - Tick-borne encephalitis virus
KW - Antivirals
KW - Monoclonal antibodies
KW - Immunotherapy
UR - https://doi.org/10.1016/j.antiviral.2022.105504
N2 - Tick-borne encephalitis (TBE) is a potentially fatal disease common in much of Europe and Asia. There is no specific therapy for the treatment of TBE patients. However, several efforts are being made to develop small molecules that specifically interfere with the life cycle of TBE virus. In particular, recently various nucleoside analogues that can inhibit the viral replicase, such as the RNA-dependent RNA polymerase or viral methyltransferases, have been explored. In addition, human or chimeric (i.e., structural chimeras that combine mouse variable domains with human constant domains) monoclonal antibodies with promising potential for post-exposure prophylaxis or early therapy have been developed. This review summarizes the latest directions and experimental approaches that may be used to combat TBE in humans.
ER -
EYER, Luděk, Katherine SELEY-RADTKE and Daniel RŮŽEK. New directions in the experimental therapy of tick-borne encephalitis. \textit{Antiviral Research}. Elsevier B.V., 2023, vol.~210, February, p.~1-6. ISSN~0166-3542. Available from: https://dx.doi.org/10.1016/j.antiviral.2022.105504.
|
